2024
Psychopharmacological Treatment of Schizophrenia
Singh N, Ganesh S, D'Souza D. Psychopharmacological Treatment of Schizophrenia. 2024 DOI: 10.1016/b978-0-323-95702-1.00177-9.Peer-Reviewed Original ResearchAntipsychotic drugsPositive symptoms of schizophreniaPharmacological treatment of schizophreniaTreatment-resistant schizophreniaPharmacological treatmentSymptoms of schizophreniaTreatment of schizophreniaAcute psychotic episodeNeuroleptic malignant syndromeNegative symptomsPositive symptomsExtrapyramidal symptomsPsychotic episodeCognitive deficitsCognitive symptomsMalignant syndromeSchizophreniaPrevent relapseSide effectsMaintenance treatmentLong-actingDopamineAssociated with significant side effectsMedication adherenceProportion of patients
2023
The Acute Effects of Cannabinoids in Patients with Psychotic Illness
Ganesh S, Henquet C, Sewell R, Kuepper R, Ranganathan M, D’Souza D. The Acute Effects of Cannabinoids in Patients with Psychotic Illness. 2023, 225-239. DOI: 10.1017/9781108943246.023.Peer-Reviewed Original ResearchMental illnessMental health teamsHealth policy implicationsHigh-potency cannabisStages of neurodevelopmentPotential adverse effectsAcute effectsHealth teamsPsychotic illnessImpact of exposureCannabis dependenceAdverse effectsIllnessCannabisCannabinoidsSynthetic cannabinoidsPsychosisNew research findingsAssociationComplex associationPatientsNeurodevelopmentPutative modelSchizophrenia
2019
O11.2. CHARACTERIZING CANNABINOID INDUCED ACUTE PERSISTENT PSYCHOSIS (CIAPP) AS A POSSIBLE SUBTYPE OF SCHIZOPHRENIA USING DEEP LEARNING
Ganesh S, Vidya K, Tikka S, Raj J, Gahalout R, Skosnik P, Luddy C, Goyal N, Ram D, D’Souza D, Cortes-Briones J. O11.2. CHARACTERIZING CANNABINOID INDUCED ACUTE PERSISTENT PSYCHOSIS (CIAPP) AS A POSSIBLE SUBTYPE OF SCHIZOPHRENIA USING DEEP LEARNING. Schizophrenia Bulletin 2019, 45: s194-s194. PMCID: PMC6455269, DOI: 10.1093/schbul/sbz021.258.Peer-Reviewed Original Research
2018
Six months' course and outcome of metabolic abnormalities in a cohort of patients with schizophrenia in rural India
Bijjal S, Ganesh S, Rawat V, Agarwal V, Reddy K, Devi N, Kumar C, Christopher R, Thirthalli J. Six months' course and outcome of metabolic abnormalities in a cohort of patients with schizophrenia in rural India. Schizophrenia Research 2018, 201: 415-416. PMID: 29880456, DOI: 10.1016/j.schres.2018.05.016.Peer-Reviewed Original Research
2016
Prevalence and determinants of metabolic syndrome in patients with schizophrenia: A systematic review and meta-analysis of Indian studies
Ganesh S, Ashok A, Kumar C, Thirthalli J. Prevalence and determinants of metabolic syndrome in patients with schizophrenia: A systematic review and meta-analysis of Indian studies. Asian Journal Of Psychiatry 2016, 22: 86-92. PMID: 27520904, DOI: 10.1016/j.ajp.2016.05.006.Peer-Reviewed Original ResearchConceptsMetabolic syndromePooled prevalenceSchizophrenia patientsLow prevalenceSystematic reviewNCEP ATP III criteriaDeterminants of MetSDrug-naïve patientsCase-control designUnderstanding of prevalenceHospital studyHigh prevalenceHospital settingPrevalence ratesPatientsScience Direct databasesCommunity settingsSyndromePrevalenceLiterature searchIndian studiesHospitalSchizophreniaGoogle ScholarConflicting results